CN105267897A - Traditional Chinese medicine composition for treating cancer osseous metastasis - Google Patents
Traditional Chinese medicine composition for treating cancer osseous metastasis Download PDFInfo
- Publication number
- CN105267897A CN105267897A CN201510893914.XA CN201510893914A CN105267897A CN 105267897 A CN105267897 A CN 105267897A CN 201510893914 A CN201510893914 A CN 201510893914A CN 105267897 A CN105267897 A CN 105267897A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating cancer osseous metastasis. The traditional Chinese medicine composition is prepared from, by weight, 8 parts to 14 parts of cassia twigs, 6 parts to 10 parts of radix paeoniae alba, 6 parts to 10 parts of liquorice, 30 parts to 60 parts of radix clematidis, 8 parts to 14 parts of radix bupleuri, 8 parts to 14 parts of scutellaria baicalensis, 8 parts to 14 parts of pericarpium citri reticulatae, 8 parts to 14 parts of curcuma aromatica, 8 parts to 14 parts of cortex moutan, 8 parts to 14 parts of notopterygium roots, 8 parts to 14 parts of radix angelicae pubescentis, 8 parts to 14 parts of radix saposhnikoviae, 1 part to 5 parts of asarum sieboldii, 8 parts to 14 parts of poria cocos, 8 parts to 14 parts of angelica sinensis, 8 parts to 14 parts of radix achyranthis bidentatae, 8 parts to 14 parts of dipsacus asperoides, 4 parts to 8 parts of rheum officinale, 8 parts to 14 parts of radices ligustici sinensis, 8 parts to 14 parts of chastetree fruits and 8 parts to 14 parts of ligusticum wallichii. The traditional Chinese medicine composition has the obvious inhibiting effect and the obvious repairing effect on various cancer patients, various metastatic tumor patients, various cancer hydrothorax and ascites patients and various osseous metastasis patients, and the anti-tumor mode achieves the positive and beneficial effect on improving the life quality and prolonging the lifetime of tumor patients.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese medicine composition of Therapeutic cancer Bone tumour.
Background technology
Bone cancer pain is the most serious a kind of cancer pain, mainly comes from the secondary Bone tumour such as primary bone tumor or pulmonary carcinoma, breast carcinoma, carcinoma of prostate, has a strong impact on the quality of life of cancer patient.Before the reported first Mouse Bone cancer pain models such as Schwei in 1999, cancer pain research is that the chronic pain model that causes in non-cancer carries out always.In fact, both pathogenesis are not identical, and effective medicine can not alleviate cancer pain in neuropathic pain treatment.In recent years, use local injection method by different tumor cell inoculations in tibial bone pulp cavity, successfully establish tibial cancer pain model, this model can be considered metastatic bone cancer pain model, for the mechanism and clinical prevention disclosing cancer pain provides effective research means.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition of Therapeutic cancer Bone tumour.
In order to realize object of the present invention, the invention provides a kind of Chinese medicine composition of Therapeutic cancer Bone tumour, it comprises the material of following weight portion: Ramulus Cinnamomi 8-14 part, Radix Paeoniae Alba 6-10 part, Radix Glycyrrhizae 6-10 part, Radix Clematidis 30-60 part, Radix Bupleuri 8-14 part, Radix Scutellariae 8-14 part, Pericarpium Citri Reticulatae 8-14 part, Radix Curcumae 8-14 part, Cortex Moutan 8-14 part, Rhizoma Et Radix Notopterygii 8-14 part, Radix Angelicae Pubescentis 8-14 part, Radix Saposhnikoviae 8-14 part, Herba Asari 1-5 part, Poria 8-14 part, Radix Angelicae Sinensis 8-14 part, Radix Achyranthis Bidentatae 8-14 part, Radix Dipsaci 8-14 part, Radix Et Rhizoma Rhei 4-8 part, Rhizoma Ligustici 8-14 part, Fructus Viticis 8-14 part and Rhizoma Chuanxiong 8-14 part.
Preferably, the Chinese medicine composition of Therapeutic cancer Bone tumour of the present invention comprises the material of following weight portion: Ramulus Cinnamomi 11 parts, the Radix Paeoniae Alba 8 parts, 8 parts, Radix Glycyrrhizae, Radix Clematidis 45 parts, Radix Bupleuri 12 parts, Radix Scutellariae 11 parts, Pericarpium Citri Reticulatae 11 parts, Radix Curcumae 11 parts, Cortex Moutan 11 parts, Rhizoma Et Radix Notopterygii 11 parts, Radix Angelicae Pubescentis 11 parts, Radix Saposhnikoviae 11 parts, Herba Asari 3 parts, 11 parts, Poria, Radix Angelicae Sinensis 11 parts, Radix Achyranthis Bidentatae 11 parts, Radix Dipsaci 11 parts, Radix Et Rhizoma Rhei 6 parts, Rhizoma Ligustici 11 parts, Fructus Viticis 11 parts and Rhizoma Chuanxiong 11 parts.
More preferably, the Chinese medicine composition of Therapeutic cancer Bone tumour of the present invention also comprises the material of following weight portion: N-[4-[4-(4-the cyano-phenyl)-4-hydroxy-piperdine-1-carbonyl] phenyl] quinoline-8-sulfonamide of 0.6 part.Such as, N-[4-[4-(4-cyano-phenyl)-4-hydroxy-piperdine-1-carbonyl] phenyl] quinoline-8-sulfonamide is disclosed in CN105121425A.
Most preferably, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
The present invention also provides N-[4-[4-(4-the cyano-phenyl)-4-hydroxy-piperdine-1-carbonyl] phenyl] purposes of quinoline-8-sulfonamide in the medicine preparing Therapeutic cancer Bone tumour, breast carcinoma.
Chinese medicine composition of the present invention has significantly suppression and repair to various cancer, metastatic tumor, cancer ascites pleural fluid and Bone tumour patient, and this antitumor mode just for improving the life quality of tumor patient, extending life cycle and playing a part actively useful.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment
Take Ramulus Cinnamomi 11 grams, the Radix Paeoniae Alba 8 grams, 8 grams, Radix Glycyrrhizae, Radix Clematidis 45 grams, Radix Bupleuri 12 grams, Radix Scutellariae 11 grams, Pericarpium Citri Reticulatae 11 grams, Radix Curcumae 11 grams, Cortex Moutan 11 grams, Rhizoma Et Radix Notopterygii 11 grams, Radix Angelicae Pubescentis 11 grams, Radix Saposhnikoviae 11 grams, Herba Asari 3 grams, 11 grams, Poria, Radix Angelicae Sinensis 11 grams, Radix Achyranthis Bidentatae 11 grams, Radix Dipsaci 11 grams, Radix Et Rhizoma Rhei 6 grams, Rhizoma Ligustici 11 grams, Fructus Viticis 11 grams and Rhizoma Chuanxiong 11 grams, pulverize, cross 100 mesh sieves, mix homogeneously obtains powder.
Experimental example
MTT (available from Sigma) physiological saline solution, is mixed with the working solution of 5mg/mL ,-20 DEG C of preservations; Dimethyl sulfoxide (DMSO) is the production of Xi'an chemical reagent factory, analytical pure.Human breast cancer cell T47D cell is purchased from bio tech ltd of upper Haifeng county longevity.
Mtt assay principle
MTT is that one can accept H
+weld.In living cells mitochondrial respiratory chain, succinate dehydrogenase and cytochrome C can make the tetrazole ring opening of MTT, generate hepatic formazan crystallization.And not containing this dehydrogenase in dead cell.The growing amount of Formazan crystallization is directly proportional to viable count, and the DMSO solution of this crystallization has maximum absorption band at 570nm place, so the amount by detecting formazan crystallization evaluates the impact of medicine on cell proliferation.
Choose human breast cancer cell T47D cell as subject cell.Four kinds of tumor cells be placed in constant temperature and humidity incubator carry out cellar culture (cultivation temperature in 37 DEG C, saturated humidity is 5%CO
2) when being cultured to exponential phase, collecting and be used for antitumor test.By the above-mentioned tumor cell preparing exponential phase with 0.02% edta solution carry out sequestration, make cell suspension, collect 100 μ L tumor cell suspension and add in ELISA Plate (96 hole), get three holes as repeated trials.Cultivate about 24h.
Test medicine 1 is: take Ramulus Cinnamomi 11 grams, the Radix Paeoniae Alba 8 grams, 8 grams, Radix Glycyrrhizae, Radix Clematidis 45 grams, Radix Bupleuri 12 grams, Radix Scutellariae 11 grams, Pericarpium Citri Reticulatae 11 grams, Radix Curcumae 11 grams, Cortex Moutan 11 grams, Rhizoma Et Radix Notopterygii 11 grams, Radix Angelicae Pubescentis 11 grams, Radix Saposhnikoviae 11 grams, Herba Asari 3 grams, 11 grams, Poria, Radix Angelicae Sinensis 11 grams, Radix Achyranthis Bidentatae 11 grams, Radix Dipsaci 11 grams, Radix Et Rhizoma Rhei 6 grams, Rhizoma Ligustici 11 grams, Fructus Viticis 11 grams and Rhizoma Chuanxiong 11 grams, pulverize, add 5000 ml waters, heating 3 hours under the condition of backflow, filter, filtrate is made to be cooled to room temperature, then through the filtering with microporous membrane of 0.25 μm.
Test medicine 2 is: take N-[4-[4-(4-cyano-phenyl)-4-hydroxy-piperdine-1-carbonyl] phenyl] quinoline-8-sulfonamide 0.1 gram, add 8000 milliliters, ultrasonic 10 minutes, then through the filtering with microporous membrane of 0.25 μm.
Test medicine 3 is: the test medicine 2 getting the filtering with microporous membrane of test medicine 1 solution of the filtering with microporous membrane of 0.25 μm of 100ml and 0.25 μm of 100ml mixes, and to obtain final product.
To take the logarithm the tumor cell of trophophase, cell density is adjusted to 2 × 10
5individual/mL, is added in 96 porocyte culture plates by every hole 200 μ L, passes into 5%CO in 37 DEG C
2incubator in cultivate 4h.Get above-mentioned test medicine 1, test medicine 2 and test medicine 3 respectively, 3 Duplicate Samples established by often kind of sample, establish the positive, negative control simultaneously, every hole adds sample liquid or each 2 μ L of blank solution, cultivates 72h, and then every hole adds MTT liquid 10 μ L, continue to cultivate 4h, 37 DEG C, the centrifugal 8min of 2000r/min, sucks supernatant.Every hole adds each 100 μ L of DMSO and to vibrate on micro oscillator 15min, and after dissolving completely to crystallization, microplate reader measures the light absorption value (OD value) at 570nm place, every hole.Get three hole mean OD value by IR%=(OD
contrast-OD
sample)/OD
contrast× 100% suppression ratio (IR%) carrying out calculation sample on cell proliferation.
Adopt mtt assay, be that positive control drug (concentration is 0.5 μM) carries out anti tumor activity in vitro evaluation with amycin, result is as follows:
| Sample | OD value | Suppression ratio % |
| Blank group | 1.12±0.05 | |
| Matched group | 1.09±0.03 | |
| Amycin | 0.26±0.01 | 76.15 |
| Test medicine 1 | 0.45±0.01 | 58.71 |
| Test medicine 2 | 0.33±0.01 | 69.72 |
| Test medicine 3 | 0.40±0.01 | 63.30 |
From the above results, medicine of the present invention has In-vitro Inhibitory Effect for human breast cancer cell T47D cell.
Claims (5)
1. the Chinese medicine composition of a Therapeutic cancer Bone tumour, it is characterized in that, it comprises the material of following weight portion: Ramulus Cinnamomi 8-14 part, Radix Paeoniae Alba 6-10 part, Radix Glycyrrhizae 6-10 part, Radix Clematidis 30-60 part, Radix Bupleuri 8-14 part, Radix Scutellariae 8-14 part, Pericarpium Citri Reticulatae 8-14 part, Radix Curcumae 8-14 part, Cortex Moutan 8-14 part, Rhizoma Et Radix Notopterygii 8-14 part, Radix Angelicae Pubescentis 8-14 part, Radix Saposhnikoviae 8-14 part, Herba Asari 1-5 part, Poria 8-14 part, Radix Angelicae Sinensis 8-14 part, Radix Achyranthis Bidentatae 8-14 part, Radix Dipsaci 8-14 part, Radix Et Rhizoma Rhei 4-8 part, Rhizoma Ligustici 8-14 part, Fructus Viticis 8-14 part and Rhizoma Chuanxiong 8-14 part.
2. the Chinese medicine composition of Therapeutic cancer Bone tumour according to claim 1, it is characterized in that, it comprises the material of following weight portion: Ramulus Cinnamomi 11 parts, the Radix Paeoniae Alba 8 parts, 8 parts, Radix Glycyrrhizae, Radix Clematidis 45 parts, Radix Bupleuri 12 parts, Radix Scutellariae 11 parts, Pericarpium Citri Reticulatae 11 parts, Radix Curcumae 11 parts, Cortex Moutan 11 parts, Rhizoma Et Radix Notopterygii 11 parts, Radix Angelicae Pubescentis 11 parts, Radix Saposhnikoviae 11 parts, Herba Asari 3 parts, 11 parts, Poria, Radix Angelicae Sinensis 11 parts, Radix Achyranthis Bidentatae 11 parts, Radix Dipsaci 11 parts, Radix Et Rhizoma Rhei 6 parts, Rhizoma Ligustici 11 parts, Fructus Viticis 11 parts and Rhizoma Chuanxiong 11 parts.
3. the Chinese medicine composition of Therapeutic cancer Bone tumour according to claim 1 and 2, it is characterized in that, it also comprises the material of following weight portion: N-[4-[4-(4-the cyano-phenyl)-4-hydroxy-piperdine-1-carbonyl] phenyl] quinoline-8-sulfonamide of 0.6 part.
4. the Chinese medicine composition of Therapeutic cancer Bone tumour according to claim 1 and 2, is characterized in that, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
5.N-[4-[4-(4-the cyano-phenyl)-4-hydroxy-piperdine-1-carbonyl] phenyl] purposes of quinoline-8-sulfonamide in the medicine preparing Therapeutic cancer Bone tumour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893914.XA CN105267897A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating cancer osseous metastasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893914.XA CN105267897A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating cancer osseous metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105267897A true CN105267897A (en) | 2016-01-27 |
Family
ID=55138286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510893914.XA Pending CN105267897A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating cancer osseous metastasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105267897A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106580936A (en) * | 2016-12-01 | 2017-04-26 | 江苏省中医院 | Application of beta-asarone to preparation of drugs for treating or preventing liver metastases of colorectal cancer |
| CN109260443A (en) * | 2018-11-26 | 2019-01-25 | 孙淳 | A kind of pharmaceutical composition for treating malignant tumour |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103394067A (en) * | 2013-03-11 | 2013-11-20 | 肖鸣春 | Cancer treating pharmaceutical composition and preparation method thereof |
-
2015
- 2015-12-08 CN CN201510893914.XA patent/CN105267897A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103394067A (en) * | 2013-03-11 | 2013-11-20 | 肖鸣春 | Cancer treating pharmaceutical composition and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106580936A (en) * | 2016-12-01 | 2017-04-26 | 江苏省中医院 | Application of beta-asarone to preparation of drugs for treating or preventing liver metastases of colorectal cancer |
| CN106580936B (en) * | 2016-12-01 | 2019-04-02 | 江苏省中医院 | Beta-Asarone treats or prevents the application in colorectal cancer hepatic metastases drug in preparation |
| CN109260443A (en) * | 2018-11-26 | 2019-01-25 | 孙淳 | A kind of pharmaceutical composition for treating malignant tumour |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014139282A1 (en) | Pharmaceutical compositions for treating cancer of genital system and preparation method therefor | |
| TWI421088B (en) | Use of extract of chinese medical composition for preparing drug for inhibiting growth of lung cancer cells | |
| CN104435594A (en) | Medicine for treating viral hemorrhagic disease of trionyx sinensis | |
| CN104225536A (en) | Traditional Chinese medicine for treating stomach ulcer and duodenal ulcer | |
| CN105267897A (en) | Traditional Chinese medicine composition for treating cancer osseous metastasis | |
| CN105687839A (en) | Traditional Chinese medicine composition for treating lung cancer, cough and hemoptysis | |
| CN104707097B (en) | Pharmaceutical composition Mongolian oak stilbene dissipates and its application in the drug for blocking hepatic precancerosis, treatment liver cancer or virus hepatitis is prepared | |
| CN104474233A (en) | Formula and preparation method of trionyx sinensis skin fester disease treating traditional Chinese medicine | |
| CN104435686A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating skin itch and eczema papulosum | |
| CN102716245B (en) | Application of traditional Chinese medicine composition in preparing medicines for resisting enterovirus 71 | |
| CN107243022A (en) | Traditional Chinese medicine pill for the treatment of cancer and preparation method thereof | |
| CN105664052A (en) | Traditional Chinese medicine composition for treating breast cancer, breast cyst, breast mass and breast pain | |
| CN104474195A (en) | Traditional Chinese medicine compound preparation for treating leucoderma and preparation method of traditional Chinese medicine compound preparation | |
| CN103356915B (en) | Decoction for treatment of asthma | |
| CN102363023A (en) | Chinese medicinal composition for treating leukemia | |
| CN101015595A (en) | Composition of schisandra fruit and asarum for treating asthma and preparing process thereof | |
| CN102139021A (en) | Chinese medicinal preparation for preventing and treating radiation and preparation method thereof | |
| CN106421074A (en) | Traditional Chinese medicine composition with anti-cancer and anti-tumor functions and preparation method thereof | |
| CN104524171A (en) | Application of traditional Chinese medicine preparation in preparing medicine for treating hepatitis | |
| CN109999158A (en) | A kind of pharmaceutical composition and its application for treating lung cancer | |
| CN105456946A (en) | Traditional Chinese medicine agentia for treating cancer | |
| CN105535657A (en) | Traditional Chinese medicine composition for treating colon cancer | |
| CN103610907B (en) | A kind of pharmaceutical composition treating oral ulcer and preparation method thereof | |
| CN105477451A (en) | Traditional Chinese medicine composition for treating cancer and cancer pain and fevers | |
| CN102698213A (en) | Traditional Chinese medicine composition for treating diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160127 |